Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Fair Value Measurements (Tables)

Note 5 - Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2016

Notes Tables

Fair Value, by Balance Sheet Grouping [Table Text Block]

		As of March 31, 2016								Fair Value Measurements
		Carrying				Fair				As of March 31, 2016
		Amount				Value				Level 1				Level 2					Level 3
Assets:
Cash and cash equivalents:
Cash		$	3,564			$	3,564			$	3,564			$	-				$	-
Money market funds			776				776				776				-					-
		$	4,340			$	4,340			$	4,340			$	-				$	-
Marketable securities:
U.S. Treasury securities		$	553			$	553			$	553			$	-				$	-
Liabilities:
Contingent consideration:
Asuragen		$	4,628			$	4,628			$	-			$	-				$	4,628
RedPath			13,921				13,921				-				-					13,921
		$	18,549			$	18,549			$	-			$	-				$	18,549